Dosage guide
Epitalon dosage
Epitalon dosing: typical range, frequency, half-life, onset, routes, reconstitution math. Evidence-tiered.
At a glance
- Typical dose
- 5mg
- Half-life
- 0.5hr
- Frequency
- daily during cycle
- Routes
- subcutaneous, intramuscular, intranasal
Protocol
- 1
Reconstitute the vial
A typical 10 mg vial reconstituted with 2 mL bacteriostatic water gives 5 mg/mL. A 5 mg dose equals 100 units on a U100 insulin syringe.
Open tool → - 2
Measure the dose
Typical Epitalon dose is 5 mg (5 to 10 mg per injection. Russian clinical protocols use 10 to 20 day daily cycles repeated 2 to 4 times per year.). Use a weight-based calculator for individual adjustments.
Open tool → - 3
Set the frequency
Administer daily during cycle. Half-life of 0.5 hours anchors the dosing interval.
Open tool → - 4
Cycle if needed
Russian protocol: 10 to 20 day daily cycles, 2 to 4 times per year. Continuous dosing has no controlled human safety data.
Open tool → - 5
Monitor for side effects
Watch for: injection-site reactions; occasional mild headache (rare). Stop or reduce dose if tolerability breaks down.
Why this dose
Synthetic tetrapeptide proposed to interact directly with DNA and chromatin to modulate tissue-specific gene expression. Reported effects include telomerase activation, increased melatonin output from pineal cells, and circadian normalization.
The typical dose (5 mg) reflects 5 to 10 mg per injection. Russian clinical protocols use 10 to 20 day daily cycles repeated 2 to 4 times per year.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.
How to administer
Epitalon is administered via the subcutaneous, intramuscular, intranasal routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose. Intranasal delivery uses a metered spray; tilt the head slightly forward and breathe gently while spraying.
Onset of action runs around 24 hours after administration. Peak effect lands near 1 weeks post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.
Half-life note: Plasma half-life is short (minutes); reported downstream effects on melatonin and gene expression persist days to weeks past dosing.
Cycling and tolerance
Russian protocol: 10 to 20 day daily cycles, 2 to 4 times per year. Continuous dosing has no controlled human safety data.
The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.
Effects to expect at typical dose
- Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation
- Russian clinical literature reports mortality reduction in elderly cohorts and improved melatonin output
- Reported telomerase activation in human somatic cell culture and lifespan extension in mice and Drosophila
- Independent Western replication is essentially absent; no FDA-standard RCTs
- Anecdotal protocols use 5 to 10 mg subcutaneously daily for 10 to 20 day cycles, 2 to 4 times yearly
- Not currently on the WADA Prohibited List
Best-graded outcomes
- D All-cause mortality in elderly cohorts (Russian trials) : Reported mortality reduction; methodological concerns limit external translation (12-year Khavinson cohort, elderly Russian patients).
- D Telomerase activation (cell culture) : Reported by Khavinson group; sparse independent replication (Human somatic cell lines).
- D Lifespan extension (animal models) : Reported lifespan extension; replication outside Khavinson group is sparse (Mice and Drosophila).
Side effects and interactions
Common side effects
- injection-site reactions
- occasional mild headache (rare)
Notable interactions
- melatonin (minor): potential additive effect on circadian and pineal output; no controlled data
Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Epitalon profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.
Regulatory snapshot
- WADA status
- unknown
- DEA / Rx
- Not scheduled (research chemical)
- Pregnancy
- Insufficient data; not recommended
- Legal status
- Not FDA approved; registered in Russia under domestic pharmaceutical framework; research-use-only grey market in US/EU
Do not use if
- pregnancy
- lactation
- active malignancy (theoretical telomerase concern)
- concurrent immunosuppression
Related calculators
Related research